Trials / Completed
CompletedNCT00744692
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (\>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients \< 21 years receiving cord blood transplantation for non-malignant disorders.
Detailed description
Myeloablative doses of chemotherapy and/or radiation therapy are employed with the primary purpose of eradicating malignant cells. Additionally, these regimens exert varying degree of immunosuppression/immunoablation that aids in reducing the likelihood of rejection by host hematopoietic cells. However, myeloablative /immunoablative regimens have also been associated with significant regimen related toxicity (RRT) and regimen related mortality (RRM) that may cause death in up to 20% of patients and significantly higher rate of severe organ dysfunction or failure. While most of these RRT occur typically in the first 100 days \[ e.g. VOD (veno occlusive disease), pulmonary or intracranial hemorrhage, multiorgan failure (MOF)\], there are significant long term toxicities of TBI and/or chemotherapy including growth impairment, gonadal dysfunction/failure, hypothyroidism, cataracts, neurocognitive impairment, and second malignancies. The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (\>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients \< 21 years receiving cord blood transplantation for non-malignant disorders. The secondary objectives are: * To describe the pace of neutrophil and platelet recovery * To evaluate the pace of immune reconstitution. * To determine the treatment related mortality, overall survival and disease free survival by days 100 and 180 post-transplant * To describe incidence of acute Graft Versus Host Disease (GVHD) (II - IV) and chronic extensive GVHD * To describe the incidence of grade 3-4 organ toxicity * To evaluate long-term complications, such as sterility, endocrinopathy, and growth failure * To evaluate the incidence of late graft failures at 2 years post-transplant
Conditions
- Non Malignant Disorders
- Immunodeficiencies
- Congenital Marrow Failures
- Hemoglobinopathies
- Inborn Errors of Metabolism
- Sickle Cell
- Thalassemia
- Lysosomal Storage Disease
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Unrelated Umbilical Cord Blood Transplant | Reduced Intensity Conditioning for unrelated umbilical cord blood transplant |
| DRUG | Reduced Intensity Conditioning |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2012-12-01
- Completion
- 2014-04-01
- First posted
- 2008-09-01
- Last updated
- 2014-08-13
- Results posted
- 2014-08-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00744692. Inclusion in this directory is not an endorsement.